About us

FOCUSED ON THE DEVELOPMENT OF TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF WORSENING AND ACUTE DECOMPENSATED HEART FAILURE

Founded in 2021, Corteria Pharmaceuticals is a privately held company developing first-in-class drugs for indications of high unmet medical need, such as heart failure, sarcopenia and obesity subpopulations. Our strategy implies innovative patient stratification and target selection based on human evidence and a better understanding of the disease biology in patients.

We are using cutting-edge methods to stratify the patients and identify those who will benefit the most from our treatments. Our focus is on worsening and acute heart failure, right heart failure, sarcopenia (including age-related sarcopenia and obesity-related sarcopenia) and obesity with established complications.

Approach

We address a large spectrum of heart failure decompensation

With more than 60 million patients worldwide, heart failure is the only category of cardiovascular disease that continues to grow due to the aging population, increased incidence of diabetes, and persistent non-fatal myocardial infarction. Pulmonary congestion is recognized as the main symptom triggering unscheduled inpatient hospitalizations or outpatient visits to diuresis clinics.

Congestion is not always associated with low cardiac output, rather it is related to the stimulation of neuro-endocrine hormones that leads to excessive renal sodium and water reabsorption. Elevated fluid retention is aggravated in patients with pre-existing chronic kidney disease. Excess body fluid retention not only instigates pulmonary congestion and breathing difficulty, it also causes pulmonary hypertension and impairs the function of the skin, liver, kidney and intestine. A rapid onset of congestion results in acute decompensated heart failure, whereas a gradual development of congestion is associated with the worsening of signs and symptoms of heart failure and currently both conditions have high unmet medical needs.

CRF2 reptide
agonist project

VASOPRESSIN NEUTRALIZING ANTIBODY PROJECT

Instead of targeting broad heterogenous chronic heart failure populations, at Corteria, we are addressing well defined heart failure subpopulations that are most likely to benefit from our treatments: learn more about Corteria Pharmaceuticals strategy and portfolio at https://lnkd.in/gncbAv4r
Corteria Pharmaceuticals team is growing with the arrival of two very valuable members: Eléonore Jouanny who will be in charge of the CMC activities of our assets and Stephane Durant des Aulnois who is our new CFO…
Francesca is a physician with 30+ years’ experience in drug development encompassing phase 1 through phase 3 registrational trials and life cycle management. Her specialized expertise is in cardio-metabolic diseases. She joined Corteria from Applied Therapeutics, a clinical-stage biotechnology company, where, as the Head of Development and later VP, Clinical and Regulatory Strategy, she

News